Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 13, 2007 Brian Lawler	Nektar's New Old Drug Pfizer returns its non-selling inhalable insulin experiment Exubera to Nektar Therapeutics today, along with $135 million in cash.
The Motley Fool April 10, 2008 Brian Lawler	Nektar Can't Squeeze Nectar From This Drug Nektar Therapeutics announced that it was putting its inhaled insulin drug, Exubera, to rest. Investors, take note.
The Motley Fool September 9, 2005 Stephen D. Simpson	Diabetics Breathing Easier Investors in Pfizer, Sanofi-Aventis, and Nektar Therapeutics might be breathing a bit easier today. The FDA's expert panel recommended approval for Exubera.
The Motley Fool January 13, 2006 Stephen D. Simpson	Pfizer Pays Sanofi to Go Away Two large pharmaceutical companies settle a dispute over inhaled insulin, and $1.3 billion changes hands. Investors, take note.
The Motley Fool May 14, 2007 Brian Lawler	Sour Results for Nektar Nektar Therapeutics announces its first-quarter financial results and plans for the future. Investors, take note.
The Motley Fool January 16, 2008 Brian Lawler	Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note.
The Motley Fool May 22, 2006 Stephen D. Simpson	Nektar Full of Potential, Risk Can inhaled insulin sales live up to investors' expectations at Nektar Therapeutics?
The Motley Fool March 16, 2010 Brian Orelli	How to Lose $114 Million in One Day You've got to be a very trusting investor to buy shares in pharmaceutical company, MannKind.
The Motley Fool December 1, 2004 Brian Gorman	Rational Exuberance Nektar received a positive boost from Pfizer's announcement that it will seek approval for Exubera, an inhaled form of insulin. The drug delivery specialist's stock promptly surged, closing up 23% yesterday.
The Motley Fool December 5, 2008 Brian Orelli	Be Kind to MannKind MannKind has good data on its inhaled insulin drug, but will the FDA approve of it and will diabetics buy it?
The Motley Fool June 19, 2009 Robert Steyer	MannKind Needs More Leaps Getting FDA approval for its inhaled-insulin product is only one hurdle for this start-up pharmaceutical.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool November 3, 2006 Brian Lawler	Nektar Worth Waiting For? Investors might be getting impatient, but the new insulin the company makes is special.
The Motley Fool February 29, 2008 Brian Lawler	Nektar Squeezing Along Nektar Therapeutics finishes a topsy-turvy 2007, and gives some good guidance for upcoming year.
The Motley Fool March 2, 2005 Bill Mann	How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns.
The Motley Fool October 22, 2007 Brian Lawler	Not Another Pfizer Pfailure As Pfizer's top execs have said before, losing patent protections on many of its top products around the same time makes for a difficult operating environment. Pfizer's third-quarter results showed just how difficult those losses were.
The Motley Fool June 11, 2010 Brian Orelli	Double-Digit Pop Because the Drug Still Works? Developments at Mannkind's shareholder meeting send stock soaring.
The Motley Fool August 6, 2007 Brian Lawler	Unhappy Delays for MannKind Two delays for the inhalable insulin developer cause the stock to drop.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
The Motley Fool March 20, 2008 Brian Lawler	The AIR's Knocked Out of Alkermes Drug developer Alkermes initiates a round of cost-cutting.
The Motley Fool December 31, 2009 Brian Orelli	2010 FDA Decisions to Watch It's a pivotal year for these drugmakers.
The Motley Fool May 6, 2008 Brian Lawler	MannKind Moves Ahead The pharmaceutical awaits pivotal data on its lead drug Technosphere.
The Motley Fool August 12, 2011 Evan Niu	One Small Step for Afrezza, One Giant Leap for MannKind Afrezza makes headway toward FDA approval.
The Motley Fool April 14, 2008 Brian Lawler	MannKind Gets Smacked by Big Brother's Bad News Bad news for a competitor sinks MannKind shares.
The Motley Fool June 26, 2009 Brian Orelli	Rumors and Safety Issues -- One Bad Combination There are rumors floating around that a study will show that use of Sanofi's insulin product, Lantus, has an increased risk of cancer.
BusinessWeek July 17, 2006 Arlene Weintraub	From Pfizer, Irrational Exubera? Pfizer's insulin inhaler may not be as big a diabetes blockbuster as expected.
The Motley Fool December 24, 2009 Brian Orelli	Another Reason to Worry About Pfizer The FDA fails to approve Lyrica for treating anxiety.
The Motley Fool October 31, 2007 Brian Lawler	Nastech Still Breathing Coming phase 2 results on four different compounds will help investors assess how well Nastech's nasally-administered drugs might sell. Investors, take note.
The Motley Fool June 27, 2005 Stephen D. Simpson	Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well.
The Motley Fool July 30, 2010 Brian Orelli	MannKind: Strengths, Weaknesses, Opportunities, Threats It's all about the inhaled insulin.
The Motley Fool April 19, 2005 Stephen D. Simpson	Pfizer Fosters Fertile Future Results in the "here and now" aren't bad, but it will take a couple of years to build growth. Of course, investors must do their own research and make their own decisions.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
The Motley Fool September 22, 2010 Brian Orelli	Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown.
The Motley Fool July 20, 2006 Stephen D. Simpson	Pfizer's Big Plans Between the launch of inhaled insulin and spending $34 billion, Pfizer has a lot on its plate. Investors, take note.
Chemistry World June 30, 2014 Phillip Broadwith	Inhaled insulin approved in US Mannkind's Affreza is aimed at reducing the need for patients to inject themselves with insulin so frequently.
The Motley Fool February 21, 2008 Brian Lawler	Learn From the Decisive Encysive Deal Encysive finally finds a buyer; Pfizer announces it will acquire the drugmaker for $195 million in cash.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool June 29, 2011 Brian Orelli	So Much Insulin, So Little Use for It MannKind settles its supply agreement with Merck.
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
The Motley Fool December 27, 2011 Brian Orelli	2011 No Dreamboat for MannKind An FDA rejection and a long wait is a bad combination.
The Motley Fool November 5, 2007 Brian Lawler	Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter.
The Motley Fool December 10, 2010 Brian Orelli	Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered.
The Motley Fool December 16, 2008 Brian Orelli	Pfizer Keeps the Change For the first time in decades, investors won't get a dividend increase.
The Motley Fool February 25, 2009 Brian Orelli	Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials.
The Motley Fool April 16, 2010 Brian Orelli	It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet.
The Motley Fool September 16, 2008 Brian Lawler	Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
Pharmaceutical Executive March 1, 2006 Ron Feemster	Holding Their Breath: Inhaled Insulin Exubera, Pfizer's inhaled-insulin therapy, is carving out a new market for diabetes drugs. Four more companies are looking for their share.